Vertex's triple combination therapy for cystic fibrosis tops Evaluate Pharma's list of most valuable late-stage projects in the pharmaceutical industry pipeline.
Evaluate Pharma, which offers clients forecasts of the pharma industry, released its annual World Preview, which includes a roster of 10 of the late-stage therapies most likely to generate the most sales in five years.
A breakdown of the 10 most valuable late-stage projects and their projected worldwide sales in 2024:
1. VX-659/VX-445 + Tezacaftor + Ivacaftor — $4.27 billion. This is Vertex's triple combination drug for cystic fibrosis. It is in phase 3 clinical trials.
2. Upadacitinib — $2.51 billion. This drug, manufactured by AbbVie, is an oral treatment for adults with rheumatoid arthritis, a chronic disease that can cause irreversible joint damage. It has been filed with the FDA for approval.
3. DS-8201 — $1.79 billion. Manufactured by Daiichi Sankyo, this is an epidermal growth factor receptor antibody that aims to treat breast cancer. It is in phase 3 clinical trials.
4. Voxelotor — $1.71 billion. Manufactured by Global Blood Therapeutics, this drug is being developed as an oral, once-daily therapy for patients with sickle cell disease. It is in phase 3 clinical trials.
5. Zolgensma — $1.64 billion. Zolgensma, approved by the FDA in May, is a one-time treatment for spinal muscular atrophy, an inherited muscle-wasting disease that is often fatal to patients before age 2.
6. Sacituzumab Govitecan — $1.6 billion. This therapy, manufactured by Immonomedics, is an antibody drug conjugate for triple-negative breast cancer. The FDA had rejected the drug due to chemistry, manufacturing and control issues unrelated to clinical or preclinical data. It has been refiled with the FDA.
7. Ozanimod — $1.52 billion. This is a drug manufactured by Celgene that aims to treat relapsing, remitting multiple sclerosis and ulcerative colitis. It has been filed with the FDA.
8. Liso-cel — $1.38 billion. This is a CAR-T cell therapy manufactured by Celgene. It is showing promising response rates in patients with high-risk diffuse large B-cell lymphoma. It is in phase 3 clinical trials.
9. Brolucizumab — $1.32 billion. This is Novartis' treatment for wet age-related macular degeneration. It has been filed with the FDA for approval.
10. LY3298176 (Tirzepatide) — $1.01 billion. This drug is manufactured by Eli Lilly. It is a dual GIP and GLP-1 receptor agonist for diabetes. It is in phase 3 clinical trials.